<DOC>
	<DOCNO>NCT01659437</DOCNO>
	<brief_summary>This WHO-sponsored trial . Combination therapy streptomycin rifampicin standard antibiotic treatment M. ulcerans infection since 2004 . In March 2010 , WHO Technical Advisory Group recommend trial carry develop fully oral treatment disease . Although current treatment effective , injection streptomycin problem . Several small observational study ( publish unpublished ) show fully oral treatment promising . This WHO sponsor study randomize , control open label non-inferiority phase II/III , multi-centre trial ( 1 centre Benin 4 centre Ghana ) , two parallel treatment group . The ultimate goal search effective alternative treatment current standard WHO-recommended therapy form Buruli ulcer , include injection streptomycin inherent logistic , operational safety disadvantage . Financial material support : 1 . American Leprosy Missions , USA 2 . Raoul Follereau Foundation , France 3 . MAP International , USA 4 . Sanofi , France 5 . 7th Framework Programme European Union : BuruliVac project ( 241500 ) 6 . Aranz Medical Limited , New Zealand</brief_summary>
	<brief_title>WHO Drug Study Buruli Ulcer - Comparison SR8 CR8</brief_title>
	<detailed_description>A total 415 patient Buruli ulcer clinically diagnose include study , consist 332 case category I II Buruli ulcer ( &lt; 10 cm ) confirm polymerase chain reaction ( PCR ) , plus 83 non PCR-confirmed Buruli ulcer . Patients randomize receive treatment two antibiotic regimen follow : ( ) Regimen I ( SR8 ) : 15 mg/kg streptomycin per day intramuscular injection 8 week plus 10 mg/kg per day oral rifampicin 8 week ; ( ii ) Regimen II ( CR8 ) : 15 mg/kg per day oral extended-release clarithromycin 8 week plus 10 mg/kg per day oral rifampicin 8 week . Assessments , course antibiotic treatment include full medical history , clinical assessment monitor vital sign , assessment lesion , laboratory investigation , hear test , electrocardiogram , pregnancy test , voluntary HIV counsel testing , functional limitation assessment . The primary efficacy parameter heal without recurrence without excision surgery 12 month start treatment . The primary endpoint assess panel expert unaware treatment ( 'single blind ' treatment allocation ) . Statistician : Mr Bruno Scherrer , Consultant , Drugs Neglected Diseases initiative , Switzerland Data Management : Mr Raymond Omollo , Drugs Neglected Diseases initiative ( DNDi ) Africa</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Buruli Ulcer</mesh_term>
	<mesh_term>Streptomycin</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Inclusion criterion : All patient ( gender ) clinical diagnosis BUD ( category : I II , crosssectional diameter â‰¤ 10cm ) agree study site treatment team lead lead clinician Exclusion criterion : 1 . Patients lesion size &gt; 10cm crosssectional diameter 2 . Children &lt; 5 year , &lt; 20 kilogram body weight 3 . Pregnancy ( selfreported , clinically diagnose , urine test ( betahCG ) positive 4 . Patients previous treatment Buruli ulcer , tuberculosis leprosy least one study drug ( rifampicin , streptomycin , clarithromycin ) 5 . Patients history hypersensitivity rifampicin and/or streptomycin and/or clarithromycin 6 . Patients previous treatment macrolide quinolone antibiotic , antituberculosis medication , immunomodulatory drug include corticosteroid within one month 7 . Patients current treatment drug likely interact study medication , e.g , anticoagulant , cyclosporin , phenytoin , phenobarbitone . Users oral contraceptive notify contraceptive less reliable take rifampicin ; alternative ( mechanical ) contraceptive method discuss study participant 8 . Patients coinfection HIV 9 . Patients history current clinical sign ascites , jaundice , partial complete deafness , myasthenia gravis , renal dysfunction ( know suspect ) , diabetes mellitus , severe immune compromise ( e.g. , immunosuppressive drug organ transplant ) , evidence ( previous ) tuberculosis , Buruli ulcer leprosy ; terminal illness ( e.g. , metastasized cancer ) 10 . Patients unable take oral medication gastrointestinal disease likely interfere drug absorption 11 . Patients know suspected bowel stricture tolerate macrolide antibiotic clarithromycin 12 . Patients mental condition , include addiction substance abuse ( alcohol , qat , etc ) likely interfere possibility comply study protocol 13 . Patients willing give inform preconsent , consent ( patient and/or parent/legal representative ) , withdrawal consent</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>M. ulcerans</keyword>
	<keyword>Buruli ulcer</keyword>
	<keyword>drug trial</keyword>
	<keyword>clarithromycin</keyword>
</DOC>